1 / 15

Presented at CTOS 2012 by Peter Reichard t on behalf of Team GRID, including:

zenda
Télécharger la présentation

Presented at CTOS 2012 by Peter Reichard t on behalf of Team GRID, including:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Updated results from the GRID trial – an international phase 3, randomized, double-blind, placebo-controlled trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (im) and sunitinib (su) Presented at CTOS 2012 by Peter Reichardton behalf of Team GRID, including: Paolo Casali, Yoon-Koo Kang, Jean-Yves Blay, Piotr Rutkowski, Hans Gelderblom, Peter Hohenberger, Michael Leahy, Margaret von Mehren, Heikki Joensuu, Robert Maki, JianmingXu, Toshirou Nishida, Christian Kappeler, Iris Kuss, Dirk Laurent,and George Demetri HELIOS Klinikum, Bad Saarow, Germany; IstitutoNazionaledeiTumori, Milan, Italy; Asan Medical Center, Seoul, South Korea; Centre Léon Bérard, Lyon, France; Maria Skłodowska-Curie Memorial Cancer Center, Warsaw, Poland; Leiden University Medical Center, Leiden, Netherlands; Mannheim University Medical Center, Mannheim, Germany; Christie NHS Foundation Trust, Manchester, UK; Fox Chase Cancer Center, Philadelphia, PA, USA; Helsinki University Central Hospital, Helsinki, Finland; Mount Sinai School of Medicine, New York, NY, USA; Affiliated Hospital of Academy Military Medical Sciences, Beijing, China; Osaka Police Hospital, Osaka, Japan; Bayer HealthCare Pharmaceuticals, Berlin, Germany; Ludwig Center at Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

  2. Regorafenib (BAY 73-4506) is a structurally distinct oral agent with a unique profile of inhibiting multiple kinases relevant to GIST Regorafenib Biochemical activity Percent control 0% 0.1% 0.1-1% 1-5% 5-10% 10-35% Wilhelm SM et al. Int J Cancer 2011; 129: 245-255.

  3. Multicenter, randomized, double-blind (DB),placebo-controlled phase 3 study Primary endpoint: progression-free survival (PFS) Global trial: 17 countries across Europe,North America, and Asia-Pacific Stratification: treatment line (2 vs >2 prior lines),geographical location (Asia vs “Rest of World”) GIST – Regorafenib In Progressive Disease (GRID): study design Regorafenib + best supportive care (BSC) 160 mg once daily 3 weeks on, 1 week off (n=133) RANDOM I ZAT I ON Metastatic/ unresectable GIST patients progressing despite at least prior imatinib and sunitinib (n=236 screened; n=199 randomized) Disease progression per independent blinded central review 2 : 1 OF F TREATMENT Placebo + BSC 3 weeks on, 1 week off (n=66) Unblinding Crossover offered for placebo arm or continued regorafenib for treatment arm Regorafenib (unblinded)until next progression

  4. Adverse events occurring in ≥20% of patients during double-blind treatment NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events HFSR: hand–foot skin reaction

  5. PFS per blinded central review (primary endpoint) Placebo, N=66 Regorafenib, N=133 Median PFS 4.8 months 0.9 months (0.9–1.1) (95% CI) (4.1–5.8) 1.00 Number of events 63 (95.5%) 81 (60.9%) 0.75 Hazard ratio (95% CI): 0.27 (0.19–0.39) 1-sided p-value: <0.0001 PFS probability Placebo 0.50 Regorafenib 0.25 0 0 50 100 150 200 250 300 Days from randomization Regorafenib significantly improved PFS vs placebo (p<0.0001)

  6. PFS perinvestigator assessment Placebo, N=66 Regorafenib, N=133 Median PFS 1.7 months 7.4 months (95% CI) (1.0–1.9) (6.5–A*) 1.00 Number of events 51 (77.3%) 48 (36.1%) Hazard ratio (95% CI): 0.22 (0.14–0.35) 1-sided p-value: <0.000001 0.75 PFS probability 0.50 0.25 Placebo Regorafenib 0 0 50 100 150 200 250 300 350 Days from randomization Regorafenib significantly improved PFS vs placebo (p<0.000001) *A: value cannot be estimated because of censored data

  7. High rate of disease control despite low overall response rate with regorafenib Responses based on modified RECIST v1.1

  8. Continuing regorafenib after progression:PFS in initial blinded phase vs post-progression Rx (investigator assessments) Continuing regorafenibafter PD N=41 Regorafenib after PD on blinded placebo N=56 Regorafenibinitial blinded Rx N=133 1.00 Median PFS 7.4 months4.5 months 5.0 months 0.75 PFS probability 0.50 Regorafenib (initial blinded Rx) 0.25 Regorafenib (post-progression, unblinded Rx) Progression on initial placebo, then crossed over to regorafenib (unblinded Rx) 0 0 50 100 150 200 250 300 350 Days (from randomization for initial blinded Rx or from first progression for unblinded Rx)

  9. Prespecified subgroup analysis: PFS per central review Hazard ratio 0.27 0.23 0.31 0.30 0.24 0.42 0.22 0.31 0.18 0.30 0.15 0.29 0.24 0.19 0.22 0.30 0.50 0.19 0.24 N 199 113 86 47 152 36 163 127 72 136 63 112 56 22 110 89 22 33 144 95% Cl (0.19, 0.39) (0.14, 0.37) (0.18, 0.54) (0.15, 0.62) (0.16, 0.37) (0.19, 0.92) (0.15, 0.34) (0.20, 0.48) (0.09, 0.34) (0.19, 0.46) (0.08, 0.30) (0.18, 0.46) (0.12, 0.48) (0.06, 0.61) (0.14, 0.37) (0.18, 0.51) (0.17, 1.73) (0.07, 0.55) (0.15, 0.36) All patients Anticancer line Region Sex Age BMI ECOG score Duration of imatinib treatment Third Fourth or more Asia Rest of world North America Not North America Male Female <65 years ≥ 65 years <25 kg/m2 25 to <30 kg/m2 ≥30 kg/m2 0 1 <6 months ≥6 to <18 months ≥18 months Favorsregorafenib Favors placebo 0 0.5 1.0 1.5 2.0 Hazard ratio (95% Cl)

  10. GRID study: OS(following 85% crossover of patients on placebo arm) Placebo 1.00 Regorafenib 0.75 Regorafenib, N=33 Placebo, N=66 Median OS Not reached Not reached Number of events 29 (21.8%) 17 (25.6%) Hazard ratio (95% CI): 0.77 (0.42–1.41) 1-sided p-value: 0.199 0.50 OS probability 0.25 0 0 50 100 150 200 250 300 350 400 Days from randomization

  11. Subgroup PFS analysis of age in regorafenib group 100 <65 years (n=90) 65–74 years (n=31) • ≥75 years (n=12) 75 PFS probability (%) 50 25 Age <65 years 65–74 years ≥75 years Median PFS (months) 5.3 4.0 5.5 0 0 2 4 6 8 10 Months from randomization Patients at risk <65 years 54 50 19 5 65–74 years 20 15 4 2 • ≥75 years 8 7 4 2

  12. Subgroup PFS analysis of requirement for dose interruption in regorafenib group 100 75 Dose interruption (n=84) No dose interruption (n=48) PFS probability (%) 50 25 Dose interruption No dose interruption Median PFS (months) 5.5 4.1 0 4 6 0 2 8 10 Months from randomization Patients at risk Dose interruption 57 49 19 6 No dose interruption 25 23 8 3

  13. Subgroup PFS analysis of requirement for dose reduction in regorafenib group 100 Dose reduction (N=46) 75 No dose reduction (N=86) PFS probability (%) 50 25 Dose reduction No dose reduction Median PFS (months) 5.5 4.1 0 0 2 4 6 8 10 Months from randomization Patients at risk Dose reduction 3 5 3 2 1 3 3 No dose reduction 4 7 4 0 1 4 6

  14. Summary • Regorafenib significantly increased PFS compared with placebo in patients with metastatic or unresectable GIST • PFS: median 4.8 vs 0.9 months, hazard ratio 0.27, p<0.0001 • Regorafenib showed PFS benefit in most patient subgroups • Post progression, regorafenib treatment showed sustained benefit • Continuing regorafenib post progression: median PFS 4.5 months • Placebo crossed over to regorafenib: median PFS 5.0 months • OS rates were not statistically different, as expected, with crossover post progression to regorafenib in the majority of placebo-treated patients • Benefit of regorafenib observed independent of: • Age of participants • Requirement for dose reduction or interruption

  15. Lead investigators: AUSTRIA Hellmut Samonigg, Thomas Brodowicz, Wolfgang Eisterer BELGIUM Patrick Schöffski CANADA Martin Blackstein, Karen Mulder, Jawaid Younus CHINA Jin Li, Shukui Qin, De Sen Wan, Jianming Xu FINLAND Heikki Joensuu FRANCE Jean-Yves Blay, Binh Bui Nguyen, Antoine Adenis, Axel Le Cesne GERMANY Peter Reichardt, Jens Chemnitz, Sebastian Bauer, Peter Hohenberger, Viktor Grünwald, Frank Mayer, Jochen Schütte ISRAEL Ofer Merimsky ITALY Elena Fumagalli, Guido Biasco, Massimo Aglietta, Giuseppe Badalamenti JAPAN Toshihiko Doi, Tatsuo Kanda, Toshirou Nishida, Yasuhide Yamada, Yoshito Komatsu, Akira Sawaki NETHERLANDS Hans Gelderblom, Winette Van der Graaf POLAND Piotr Rutkowski SINGAPORE Richard Quek SOUTH KOREA Yoon-Koo Kang, Hyuk Chan Kwon, Seock-Ah Im, Joon Oh Park, Sun Young Kim SPAIN Claudia M Valverde Morales, Xavier Garcia Del Muro UK Ian Judson, Michael Leahy, Anne Thomas USA George Demetri, Mary Louise Keohan, Michael Heinrich, Margaret von Mehren, Robin Jones, Bruce Brockstein, Pamela Kaiser, Keith Skubitz, Michael Gordon The GRID trial was sponsored by Bayer HealthCare AG, Leverkusen, Germany Thanks to patients, families, and colleagues at all of the investigating centers

More Related